Literature DB >> 3885032

Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro.

D J Hammond, J R Burchell, M Pudney.   

Abstract

The effects of the hydroxynaphthoquinone BW58C on some metabolite levels and the flux of H14CO3 through the de novo pyrimidine biosynthetic pathway of intact Plasmodium falciparum have been studied in vitro using HPLC techniques. 800 nM BW58C appeared to have no significant effect on the energy status of isolated P. falciparum, but at 0.1 nM it caused a dramatic decrease in the concentrations of pyrimidine nucleotides, specifically UTP, during 256 min of incubation. Although about one hour was required to achieve a significant decrease in pyrimidine nucleotide concentrations, a much more rapid inhibition of the flux of H14CO3 through the de novo pathway was found upon addition of 0.1 nM BW58C. This inhibition caused about a 10 fold increase in the radioactivity of carbamoyl-aspartate over a 64 min period, and an overall increase in the concentration of this metabolite of about 3 fold during 256 min of incubation. These effects of BW58C against P. falciparum in vitro are discussed in terms of inhibition of de novo pyrimidine biosynthesis at the site of dihydroorotate dehydrogenase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3885032     DOI: 10.1016/0166-6851(85)90109-4

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  23 in total

Review 1.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients.

Authors:  R Dixon; A L Pozniak; H M Watt; P Rolan; J Posner
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro.

Authors:  D C McFadden; F Seeber; J C Boothroyd
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 4.  Purine and pyrimidine pathways as targets in Plasmodium falciparum.

Authors:  María Belén Cassera; Yong Zhang; Keith Z Hazleton; Vern L Schramm
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

5.  Disposition of atovaquone in humans.

Authors:  P E Rolan; A J Mercer; E Tate; I Benjamin; J Posner
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro.

Authors:  P K Rathod; A Khatri; T Hubbert; W K Milhous
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

7.  Plasmodium falciparum CTP:phosphocholine cytidylyltransferase expressed in Escherichia coli: purification, characterization and lipid regulation.

Authors:  H J Yeo; M P Larvor; M L Ancelin; H J Vial
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

8.  Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance.

Authors:  S Gassis; P K Rathod
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 9.  Antimalarial drugs. An update.

Authors:  D C Warhurst
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

10.  Examination of some factors responsible for a food-induced increase in absorption of atovaquone.

Authors:  P E Rolan; A J Mercer; B C Weatherley; T Holdich; H Meire; R W Peck; G Ridout; J Posner
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.